KRAS mutation status is highly homogeneous between areas of the primary tumor and the corresponding metastasis of colorectal adenocarcinomas: one less problem in patient care.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  American Journal of Cancer Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 28979819PMCID PMC5622231
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas.

  2016cited by this paper
• Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015.

  2016cited by this paper
• RAS mutations vary between lesions in synchronous primary colorectal cancer: testing only one lesion is not sufficient to guide anti-EGFR treatment decisions

  2015cited by this paper
• KRAS gene mutation in a series of unselected colorectal carcinoma patients with prognostic morphological correlations: a pyrosequencing method improved by nested PCR.

  2015cited by this paper
• Changes of KRAS Exon 2 Codon 12/13 Mutation Status in Recurrent Colorectal Cancer

  2015cited by this paper
• Tumor Heterogeneity Revealed by KRAS, BRAF, and PIK3CA Pyrosequencing: KRAS and PIK3CA Intratumor Mutation Profile Differences and Their Therapeutic Implications

  2014cited by this paper
• KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma

  2014cited by this paper
• Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions

  2014cited by this paper
• Degraded DNA may induce discordance of KRAS status between primary colorectal cancer and corresponding liver metastases

  2014cited by this paper
• Molecular diagnostics

  2014cited by this paper
• Mutation analysis of KRAS in primary colorectal cancer and matched metastases by means of highly sensitivity molecular assay.

  2013cited by this paper
• Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.

  2013cited by this paper
• KRAS mutations in primary and metastatic colorectal cancer

  2013cited by this paper
• The causes and consequences of genetic heterogeneity in cancer evolution

  2013cited by this paper
• Comprehensive molecular characterization of human colon and rectal cancer

  2012cited by this paper
• KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment

  2012cited by this paper
• Comparative genomic analysis of primary versus metastatic colorectal carcinomas.

  2012cited by this paper
• Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.

  2012cited by this paper
• Concordant KRAS Mutations in Primary and Metastatic Colorectal Cancer Tissue Specimens: A Meta-Analysis and Systematic Review

  2012cited by this paper
• KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer

  2012cited by this paper
• KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications.

  2011cited by this paper
• Does Neoadjuvant Therapy Alter KRAS and/or MSI Results in Rectal Adenocarcinoma Testing?

  2011cited by this paper
• Intra-tumoral Heterogeneity of KRAS and BRAF Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing

  2011cited by this paper
• KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients

  2011cited by this paper
• Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy

  2011cited by this paper
• The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM

  2010cited by this paper
• KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies

  2010cited by this paper
• KRAS and BRAF Mutational Status in Primary Colorectal Tumors and Related Metastatic Sites: Biological and Clinical Implications

  2010cited by this paper
• KRAS Mutation Testing in Human Cancers: The Pathologist's Role in the Era of Personalized Medicine

  2010cited by this paper
• NRAS Mutations Are Rare in Colorectal Cancer

  2010cited by this paper
• American Society of Clinical Oncology 2010 colorectal update

  2010cited by this paper
• Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer

  2009cited by this paper
• KRAS Mutation Testing in Colorectal Cancer

  2009cited by this paper
• American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

  2009cited by this paper
• KRAS Mutations in Primary Colorectal Cancer Tumors and Related Metastases: A Potential Role in Prediction of Lung Metastasis

  2009cited by this paper
• Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

  2009cited by this paper
• KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program

  2008cited by this paper
• Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  2008cited by this paper
• High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.

  2008cited by this paper
• Epigenetic profiling of synchronous colorectal neoplasias by quantitative DNA methylation analysis

  2006cited by this paper
• K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study.

  2003cited by this paper
• Cancer chemotherapy and somatic cell mutation.

  2000cited by this paper
• Genetic Alterations During Colorectal-Tumor Development

  1989cited by this paper
• Genetic alterations during colorectal-tumor development.

  1988cited by this paper

• Oncogenic KRAS Mutations Confer a Unique Mechanotransduction Response to Peristalsis in Colorectal Cancer Cells

  2024cites this paper
• Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications

  2023cites this paper
• Radiomics and Radiogenomics in Evaluation of Colorectal Cancer Liver Metastasis

  2022cites this paper
• The current understanding on the impact of KRAS on colorectal cancer.

  2021cites this paper
• Prognostic Factors of Colorectal Cancer: A Comparative Study on Patients With or Without Liver Metastasis

  2021cites this paper
• Prognostic and predictive biomarkers in metastatic colorectal cancer constant and evolutionary perspectives

  2021cites this paper
• KRAS mutation status concordance between the primary tumor and the corresponding metastasis in patients with rectal cancer

  2020cites this paper
• High mutational concordance between primary colorectal tumors and associated pulmonary metastases

  2020cites this paper
• A novel patient-derived organoids-based xenografts model for preclinical drug response testing in patients with colorectal liver metastases

  2020cites this paper
• Intratumor heterogeneity: A new perspective on colorectal cancer research

  2020cites this paper
• The Contribution of Evolutionary Game Theory to Understanding and Treating Cancer

  2020cites this paper
• Bayesian hierarchical meta‐analytic methods for modeling surrogate relationships that vary across treatment classes using aggregate data

  2020cites this paper
• A Bayesian hierarchical meta-analytic method for modelling surrogate relationships that vary across treatment classes

  2019cites this paper
• KRAS mutational status impacts pathologic response to pre-hepatectomy chemotherapy: a study from the International Genetic Consortium for Liver Metastases.

  2019cites this paper
• Biomarker concordance between primary colorectal cancer and its metastases

  2019cites this paper
• Oncogenic KRAS hotspot mutations are rare in IDH‐mutant gliomas

  2019cites this paper
• RAS-mediated oncogenic signaling pathways in human malignancies.

  2019cites this paper
• Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?

  2018cites this paper